In vivo effects of the putative cognitive enhancer KA-672.HCl in comparison with 8-hydroxy-2-(di-N-propylamino)tetralin and haloperidol on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 24, Issue 2, 2000, Pages 337-348

  Teismann, Peter ^a   Ferger, Boris ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

DOPAC; Dopamine; KA 672.HCl; Neuroleptic; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ANSECULIN; DOPAMINE; HALOPERIDOL; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; MALE; NONHUMAN; RAT; SEROTONIN METABOLISM; SEROTONINERGIC SYSTEM; TISSUE DISTRIBUTION;

3,4-DIHYDROXYPHENYLACETIC ACID; 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BENZOPYRANS; CEREBRAL CORTEX; COGNITION; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; HALOPERIDOL; INJECTIONS, INTRAPERITONEAL; MALE; PIPERAZINES; RATS; SEROTONIN;

EID: 0034143628     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(99)00088-3     Document Type: Article

References (16)

1. Benloucif S., Keegan M. J. and Galloway M. P. (1992) Serotonin facilitated dopamine release in vivo: Pharmacological characterization. J Pharmacol Exp Ther 265: 373-377.
2. Blandina P., Goldfarb J., Craddock-Royal B. and Green J. P. (1989) Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in rat striatum. J Pharmacol Exp Ther 251: 803-809.
3. Ferger B., Kropf W. and Kuschinsky K. (1994) Studies on electroencephalogram (EEG) in rats suggest that moderate doses of cocaine or d-amphetamine activate D1 rather than D2 receptors. Psychopharmacology 114: 297-308.
4. Frazer A. and Hansler J. G. (1999) Serotonin. In: Basic Neurochemistry, G. J. Siegel, B. W. Agranoff, R. W. Albers, S.K. Fisher and M. D. Uhler (Eds.), pp 263-292 Raven Press Ltd., New York.
5. 1A-receptors. In: Serotoninergic neurons and 5-HT receptors in the CNS, H. G. Baumgarten and M. Göthert (Eds.), pp 239-268, Springer, Berlin Heidelberg New York.
6. Imperato A. and Chiara G. D. (1985) Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J of Neurosci 5: 297-306.
7. Klusa V., Germane S., Chatterjee S. S. And Nöldner M. (1994) KA-672.HCl: A new orally active antidementia agent. Eur J Pharm Sci 2: Abst P19.
8. 1A receptor effects of BMY-14802 on serotonin release in dorsal raphe and hippocampus. Eur J Pharm 317: 49-54.
9. 1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 286: 1341-1355.
10. National Research Council (1985) Guide for the care and use of laboratory animals, NIH publication no. 85-23, Public Health Service, Bethesda, MD.
11. Nöldner M. and Chatterjee S. S. (1997) Modulation of neurotransmitter by anseculin. Pharmacol Toxicol 80, Suppl 1.
12. Nöldner M., Hauer H. and Chatterjee S. S. (1996) Anseculin Hydrochloride. Drugs of the future 21: 779-781.
13. 1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 96: 283-290.
14. Sourgens H., Hoerr R., Biber A., Steinbrede H. and Derendorf H. (1998) KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers. J Clin Pharmacol 38: 373-381.
15. Ungerstedt U. (1984) Measurement of neurotransmitter release by intracranial dialysis. In: Measurement of neurotransmitter release in vivo, Marsden CA (Eds.), pp 81-105, John Wiley & Sons Ltd., New York.
16. 1A Component. Pharmacol Biochem Behav 60: 703-707.